Mucormycosis in South America: A review of 143 reported cases
- PMID: 31192488
- PMCID: PMC6852100
- DOI: 10.1111/myc.12958
Mucormycosis in South America: A review of 143 reported cases
Abstract
Mucormycosis is a rare but important invasive fungal disease that most often affects immunocompromised hosts. The incidence of mucormycosis appears to be increasing worldwide, as risk factors such as the use of immunosuppressive therapies become more common. We report the results of a literature review of 143 mucormycosis cases reported in South America between 1960 and 2018. The number of reported cases has increased by decade, from 6 in the 1960s to 51 in the 2010s. The most common underlying conditions associated with mucormycosis in South America were diabetes mellitus (42.0%) and penetrating trauma/burns (20.0%). Underlying conditions involving immunosuppression, including treatment of haematologic malignancy, solid organ transplant, and corticosteroid use, also accounted for a large proportion of cases (45.5%). Between 1960 and 2018, cases of mucormycosis associated with conditions involving immunosuppression accounted for the highest mortality rate (58.5%), followed by diabetes mellitus (45.0%), and penetrating trauma/burns (37.9%). Overall mortality decreased from 100% to 39.4% during this period, mainly driven by the increasing availability and use of antifungal therapies and surgical intervention. However, these treatments are not yet universally utilised across the region in the treatment of mucormycosis; efforts to improve availability of effective treatments would be likely to improve outcomes.
Keywords: Brazil; South America; antifungal agents; invasive fungal disease; mucormycosis; systemic infection.
© 2019 The Authors Mycoses Published by Blackwell Verlag GmbH.
Conflict of interest statement
ME and KH are employees of Basilea Pharmaceutica International Ltd. MN has received honoraria from AbbVie, Astellas, Gilead, Janssen, Merck, Pfizer, Teva and United Medical.
Figures



Similar articles
-
Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature.Mycoses. 2020 Oct;63(10):1060-1068. doi: 10.1111/myc.13123. Epub 2020 Aug 29. Mycoses. 2020. PMID: 32485012
-
How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients.Transplantation. 2018 Nov;102(11):1815-1823. doi: 10.1097/TP.0000000000002353. Transplantation. 2018. PMID: 29975240 Review.
-
Invasive mucormycosis in children with cancer: A retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association.Mycoses. 2019 Feb;62(2):165-170. doi: 10.1111/myc.12862. Epub 2018 Nov 13. Mycoses. 2019. PMID: 30338581
-
Defining standards of CARE for invasive fungal diseases in solid organ transplant patients.J Antimicrob Chemother. 2019 Mar 1;74(Suppl 2):ii16-ii20. doi: 10.1093/jac/dkz039. J Antimicrob Chemother. 2019. PMID: 31222312 Review.
-
Gastrointestinal mucormycosis in immunocompromised hosts.Mycoses. 2015 Dec;58(12):714-8. doi: 10.1111/myc.12419. Epub 2015 Oct 12. Mycoses. 2015. PMID: 26456920 Review.
Cited by
-
Rhino-orbito-cerebral mucormycosis caused by Rhizopus microsporus var. microsporus in a diabetic patient with COVID-19.An Bras Dermatol. 2022 Jul-Aug;97(4):501-504. doi: 10.1016/j.abd.2022.02.001. Epub 2022 Jun 9. An Bras Dermatol. 2022. PMID: 35691738 Free PMC article.
-
Antifungal stewardship: the Latin American experience.Antimicrob Steward Healthc Epidemiol. 2023 Dec 5;3(1):e217. doi: 10.1017/ash.2023.471. eCollection 2023. Antimicrob Steward Healthc Epidemiol. 2023. PMID: 38156226 Free PMC article. Review.
-
Promising Antifungal Molecules against Mucormycosis Agents Identified from Pandemic Response Box®: In Vitro and In Silico Analyses.J Fungi (Basel). 2023 Jan 31;9(2):187. doi: 10.3390/jof9020187. J Fungi (Basel). 2023. PMID: 36836302 Free PMC article.
-
Storm of a rare opportunistic life threatening mucormycosis among post COVID-19 patients: A tale of two pathogens.Int J Crit Illn Inj Sci. 2022 Jan-Mar;12(1):38-46. doi: 10.4103/ijciis.ijciis_48_21. Epub 2022 Mar 24. Int J Crit Illn Inj Sci. 2022. PMID: 35433396 Free PMC article. Review.
-
Combat trauma-related invasive fungal wound infections.Curr Fungal Infect Rep. 2020 Jun;14(2):186-196. doi: 10.1007/s12281-020-00385-4. Epub 2020 Apr 16. Curr Fungal Infect Rep. 2020. PMID: 32665807 Free PMC article.
References
-
- Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859‐1867. - PubMed
-
- Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23‐34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources